In a 60-year-old man with a CT angiogram showing several moderate-to-large emboli in both lungs involving multiple lobar and segmental arteries, is the number of clots typical for patients with pulmonary embolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Multiple Moderate-to-Large Emboli Involving Lobar and Segmental Arteries is Typical for Pulmonary Embolism

The presentation described—several moderate-to-large emboli in both lungs involving multiple lobar and segmental arteries—represents a common pattern of acute PE, with segmental involvement occurring in approximately 86% of cases and lobar involvement in 41% of acute PE patients 1.

Distribution Pattern Analysis

The bilateral, multi-level involvement you describe aligns with typical PE patterns:

  • Segmental arteries are the most frequently involved (86% of cases), followed by lobar arteries (41%) 1
  • Bilateral PE occurs in approximately 65% of cases, making it more common than unilateral involvement 1
  • Multiple emboli are the norm rather than the exception—in one study, saddle emboli (which extend across vessel bifurcations) were present in 67% of PE patients, with patients having 1-10 saddle emboli each 2

The lower lobe branches (right 55%, left 53%) and upper lobe branches (right 47%, left 41%) are the most common anatomic sites 1.

Clinical Significance vs. Thrombus Burden

A critical caveat: The number and location of clots does NOT reliably predict mortality or guide treatment decisions 3. The 2026 AHA/ACC guidelines explicitly recommend against using quantification of angiographic thrombus burden for short-term risk stratification (Class 3: No Benefit recommendation) 3.

Key evidence supporting this:

  • A meta-analysis of 19 studies found no direct correlation between high obstruction index and prognosis; paradoxically, lower obstruction indices showed increased mortality (OR 2.24) 3
  • A prospective study of 271 PE patients showed no association between thrombus burden and adverse clinical events after excluding hemodynamically unstable patients 3
  • Clot volume measurements, while strongly correlated with semiquantitative scores, were not independently associated with short-term mortality 4

What Actually Matters for Risk Stratification

Instead of counting clots, focus on:

  1. Hemodynamic status (presence of shock or hypotension)
  2. Right ventricular dysfunction on imaging (RV/LV ratio >1.0 is the only CT finding independently associated with mortality) 4
  3. Biomarkers (troponin, BNP/NT-proBNP)
  4. Clinical risk scores (not anatomic burden)

The 2026 PE-RADS reporting system emphasizes anatomic location (central vs. peripheral) and right heart function assessment rather than clot counting 5.

Practical Implications

While this patient's multi-level bilateral involvement is typical, treatment decisions should be based on the AHA/ACC PE Categories (A-E) that incorporate hemodynamics, biomarkers, and RV function—not on the number or size of visible clots 3, 6. The anatomic characterization becomes relevant only when considering advanced therapies (catheter-directed intervention, surgical embolectomy) in selected high-risk patients 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.